From: Hyperlipidemia and mortality in patients on peritoneal dialysis
Over the overall follow-up period | From 48-month follow up onwards | |||||
---|---|---|---|---|---|---|
Non-hyperlipidemia | Hyperlipidemia | P-value | Non-hyperlipidemia | Hyperlipidemia | P-value | |
N | 2406 | 533 | 912 | 158 | ||
Age, years | 49.0 (38.0–60.0) | 54.0 (43.0–64.0) | < 0.001 | 46.0 (37.0–57.0) | 52.0 (42.2–63.0) | < 0.001 |
Men, % | 1423 (59.1%) | 274 (51.4%) | 0.001 | 544 (59.6%) | 79 (50.0%) | 0.023 |
Body mass index, kg/m2 | 22.1 ± 6.3 | 23.0 ± 3.8 | 0.113 | 22.1 ± 6.3 | 23.0 ± 3.8 | 0.113 |
Systolic BP, mmHg | 140.8 ± 26.2 | 141.9 ± 25.2 | 0.652 | 140.8 ± 26.2 | 141.9 ± 25.2 | 0.652 |
Diastolic BP, mmHg | 89.5 ± 16.7 | 87.0 ± 15.4 | 0.088 | 89.5 ± 16.7 | 87.0 ± 15.4 | 0.088 |
24-hour urine volume, mL | 800 (450–1200) | 825 (500–1288) | 0.249 | 800 (450–1200) | 825 (500–1288) | 0.249 |
Current smoking, (%) | 228 (9.5%) | 66 (12.4%) | 0.043 | 60 (6.6%) | 21 (13.3%) | 0.003 |
Current alcohol consumption, (%) | 82 (3.4%) | 26 (4.9%) | 0.103 | 18 (2.0%) | 9 (5.7%) | 0.006 |
Charlson comorbidity index | 3.3 ± 0.6 | 3.6 ± 0.8 | < 0.001 | 3.2 ± 0.5 | 3.5 ± 0.7 | < 0.001 |
Diabetes mellitus, (%) | 371 (15.4%) | 178 (33.4%) | < 0.001 | 97 (10.6%) | 42 (26.6%) | < 0.001 |
Hypertension, (%) | 1527 (63.5%) | 388 (72.8%) | < 0.001 | 538 (59.0%) | 110 (69.6%) | 0.012 |
A history of CVD, (%) | 274 (11.4%) | 136 (25.5%) | < 0.001 | 94 (10.3%) | 26 (16.5%) | 0.024 |
Calcium channel blockers, (%) | 1496 (62.2%) | 358 (67.2%) | < 0.001 | 502 (55.0%) | 98 (62.0%) | < 0.001 |
Beta blockers, (%) | 923 (38.4%) | 290 (54.4%) | < 0.001 | 388 (42.5%) | 85 (53.8%) | 0.009 |
Diuretics, (%) | 181 (7.5%) | 19 (3.6%) | 0.001 | 43 (4.7%) | 7 (4.4%) | 0.876 |
ACEI/ARBs, (%) | 760 (31.6%) | 252 (47.3%) | < 0.001 | 329 (36.1%) | 83 (52.5%) | < 0.001 |
Aspirin, (%) | 183 (7.6%) | 61 (11.4%) | 0.004 | 58 (6.4%) | 33 (20.9%) | < 0.001 |
Statins, (%) | 269 (11.2%) | 147 (27.6%) | < 0.001 | 58 (6.4%) | 26 (16.5%) | < 0.001 |
Hemoglobin, g/dL | 9.1 (2.8) | 10.0 (2.7) | < 0.001 | 9.2 ± 3.0 | 10.1 ± 2.5 | < 0.001 |
Serum albumin, g/dL | 3.5 (0.6) | 3.4 (0.5) | 0.449 | 3.5 ± 0.6 | 3.4 ± 0.5 | 0.587 |
Serum uric acid, mg/dL | 6.9 (2.4) | 6.9 (2.3) | 0.696 | 6.9 ± 2.5 | 7.1 ± 2.2 | 0.325 |
eGFR, mL/min/1.73 m2 | 6.5 (4.7–8.3) | 6.4 (4.7–8.3) | 0.976 | 6.5 (4.7–8.3) | 6.3 (4.4–8.2) | 0.208 |
Cholesterol, mg/dL | 151.2 (117.2–182.0) | 154.7 (121.4-185.6) | 0.117 | 149.3 (116.4-183.1) | 161.8 (129.2-189.9) | 0.023 |
Triglyceride, mg/dL | 94.8 (56.7-153.3) | 92.1 (55.8-151.6) | 0.753 | 94.8 (57.4-154.2) | 87.7 (53.2-152.6) | 0.720 |
High-density lipoprotein, mg/dL | 39.4 (31.3–49.9) | 39.6 (31.8–49.1) | 0.939 | 39.4 (29.8–48.8) | 38.3 (32.7–49.5) | 0.611 |
Low-density lipoprotein, mg/dL | 81.3 (47.4-116.3) | 83.9 (48.7-119.9) | 0.127 | 80.4 (49.8-117.5) | 83.3 (41.0-121.0) | 0.527 |
hs-CRP, mg/L | 4.3 (1.9–14.0) | 4.5 (1.9–16.0) | 0.622 | 4.2 (1.9–13.2) | 4.9 (2.0-18.5) | 0.065 |